{"bill": {"#text": "\n  ", "form": {"current-chamber": {"#tail": "\n    ", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n    ", "congress": {"#tail": "\n    ", "#text": "113th CONGRESS"}, "#tail": "\n  ", "legis-num": {"#tail": "\n    ", "#text": "S. 621"}, "official-title": {"#tail": "\n  ", "#text": "To amend the Controlled Substances Act to make any\n\t\t  substance containing hydrocodone a schedule II drug."}, "session": {"#tail": "\n    ", "#text": "1st Session"}, "distribution-code": {"#tail": "\n    ", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": "\n      ", "@date": "20130320", "#text": "March 20, 2013"}, "#tail": "\n    ", "action-desc": {"#tail": "\n    ", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "SSJU00", "#text": "Committee on the\n\t\t\t Judiciary"}, "sponsor": {"#tail": "(for\n\t\t\t himself,", "#text": "Mr. Manchin", "@name-id": "S338"}, "cosponsor": [{"#tail": ",", "#text": "Mr. Kirk", "@name-id": "S339"}, {"#tail": ",", "#text": "Mrs. Feinstein", "@name-id": "S221"}, {"#tail": ",", "#text": "Mr. Rockefeller", "@name-id": "S176"}, {"#tail": ", and", "#text": "Mrs.\n\t\t\t Gillibrand", "@name-id": "S331"}, {"#tail": ")\n\t\t\t introduced the following bill; which was read twice and referred to the", "#text": "Mr. Schumer", "@name-id": "S270"}]}, "#text": "\n      "}, "legis-type": {"#tail": "\n    ", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-Senate", "@public-private": "public", "legis-body": {"#tail": "\n", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "#text": "Safe Prescribing Act of\n\t\t\t 2013"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "idF3AAD1A617BC44EF96B776D1088C2F14"}, {"@section-type": "subsequent-section", "#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Hydrocodone\n\t\t\t amendment"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "Schedule III(d) in", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "is amended\n\t\t\t by\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "(", "@entity-type": "act", "#text": "section 202 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:202"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "@parsable-cite": "usc/21/812", "#text": "21 U.S.C. 812", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "and", "@entity-type": "act", "#text": "paragraphs (3)", "@value": "Controlled Substances Act/s:202/p:3"}, {"#tail": "; and", "@entity-type": "act", "#text": "(4)", "@value": "Controlled Substances Act/s:202/p:4"}], "#text": "striking", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "idDA316AFF8843449E9CF3FAF0D8CE1A0B", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "as", "@entity-type": "act", "#text": "paragraphs (5), (6), (7), and\n\t\t\t (8)", "@value": "Controlled Substances Act/s:202/p:5,6,7,8"}, {"#tail": ", respectively.", "@entity-type": "act", "#text": "paragraphs (3), (4), (5), and (6)", "@value": "Controlled Substances Act/s:202/p:3,4,5,6", "@proposed": "true"}], "#text": "redesignating", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "idDD09F572A1824C729AA174A9909DDB23", "#text": "\n          "}], "#text": "\n        ", "@id": "id0F0C5ED9702E4289BF00B4ABF691866B"}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "shall take effect on\n\t\t\t the date that is 6 months after the date of enactment of this Act.", "@entity-type": "act", "#text": "subsection (a)", "@value": "Safe Prescribing Act of 2013/s:2/ss:a", "@proposed": "true"}, "#text": "The amendments made by"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Effective\n\t\t\t date"}, "#text": "\n        ", "@id": "id4E7EBC62782946169CD275E9D8D99261"}], "#text": "\n      ", "@id": "idB49043BCCF384A1483A6EEB89A0CB81B"}, {"#tail": "\n    ", "text": {"#tail": "\n    ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the", "@entity-type": "act", "#text": "section 2", "@value": "Safe Prescribing Act of 2013/s:2", "@proposed": "true"}, {"#tail": "shall immediately, without regard to", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ", amend", "@entity-type": "uscode", "#text": "chapter 5\n\t\t\t of title 5, United States Code", "@value": "usc-chapter/5/5"}], "#text": "Notwithstanding the amendments made by", "external-xref": {"#tail": "of title 21, Code of\n\t\t\t Federal Regulations, relating to the physical security controls for\n\t\t\t non-practitioners, narcotic treatment programs and compounders for narcotic\n\t\t\t treatment programs, and storage areas for controlled substances, to allow, for\n\t\t\t the 3-year period beginning on the date of enactment of this Act, manufacturers\n\t\t\t and distributors to store hydrocodone combination products in accordance with\n\t\t\t the physical security requirements for schedule III, IV, and V controlled\n\t\t\t substances.", "@parsable-cite": "usc/21/1301", "#text": "section 1301.72", "@legal-doc": "usc"}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Physical\n\t\t\t security requirements"}, "#text": "\n      ", "@id": "id5C2CDBAACC034FFF9C933C1BFF49B11E"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "GAO\n\t\t\t report"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "shall submit to", "@entity-type": "federal-body", "#text": "Comptroller General of the\n\t\t\t United States", "@entity-id": "0500"}, {"#tail": "a report on the reclassification of\n\t\t\t hydrocodone products under this Act.", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Not later than 18\n\t\t\t months after the date of enactment of this Act, the", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "id0E4EB6C7D1424A3783F7ECEF2B3960AE"}, {"#tail": "\n    ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "shall include\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Safe Prescribing Act of 2013/s:4/ss:a", "@proposed": "true"}, "#text": "The\n\t\t\t report required under"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Contents"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "an assessment of\n\t\t\t the degree to which the reclassification of hydrocodone products under this Act\n\t\t\t impacts the ability of patients with legitimate medical needs, particularly\n\t\t\t those in rural areas and nursing home facilities, to access adequate pain\n\t\t\t management; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "idF994C2C8020D444FB4754CB52B802084", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "recommendations\n\t\t\t necessary to address issues, if any, relating to patient access to adequate\n\t\t\t pain management."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "idBC7B44F522184CB79D834C387C96342F", "#text": "\n          "}], "#text": "\n        ", "@id": "id5EC90FD500E444B38C314B540D9C3E40"}], "#text": "\n      ", "@id": "idC36B04F5396A44CB92EADCD629036C75"}], "#text": "\n    "}, "metadata": {"#tail": "\n  ", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n      ", "#text": "2013-03-20"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n      ", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n      ", "#text": "EN"}, "#tail": "\n  ", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n      ", "#text": "113 S621 IS: Safe Prescribing Act of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n    ", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n      ", "#text": "U.S. Senate"}, "#text": "\n      "}, "#text": "\n    "}}}